Shanghai Pharmaceuticals Holding Co Ltd (2607:HK) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Shanghai Pharmaceuticals Holding Co Ltd stock forecast from 0 analysts, the average analyst target price for Shanghai Pharmaceuticals Holding Co Ltd is not available over the next 12 months. Shanghai Pharmaceuticals Holding Co Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Shanghai Pharmaceuticals Holding Co Ltd is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Shanghai Pharmaceuticals Holding Co Ltd’s stock price was HKD 10.78. Shanghai Pharmaceuticals Holding Co Ltd’s stock price has changed by -2.18% over the past week, -9.41% over the past month and -30.27% over the last year.
No recent analyst target price found for Shanghai Pharmaceuticals Holding Co Ltd
No recent average analyst rating found for Shanghai Pharmaceuticals Holding Co Ltd
Company Overview Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in China and internationally. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including anti-tumor, heart and cerebral vessels, psychoneural, anti-infection, auto-immunity, digestive tract and metabolism, and respiratory system. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores, and online drug business. Shanghai Pharmaceuticals Holding Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, China. Read Less
Shanghai Pharmaceuticals Holding Co., Ltd. researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in China and internationally. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemica...Read More
Frequently Asked Questions About Shanghai Pharmaceuticals Holding Co Ltd (2607:HK) Stock
Stock Target Advisor's fundamental analysis for Shanghai Pharmaceuticals Holding Co Ltd's stock is Slightly Bullish .
2607:HK stock's dividend yield is 6.52%.
Our analysis grades 2607:HK stock's dividend yield at B. This means that 2607:HK stock's dividend yield is above 86% of the stocks in the Medical Distribution sector in the HK exchange.
Based on this 2607:HK may be a good dividend stock for its sector.
Unfortunately we do not have enough data on 2607:HK's stock to indicate what its average analyst target is.
2607:HK stock's Price/Earning ratio is 7.89.
Our analysis grades 2607:HK stock's Price / Earning ratio at D+. This means that 2607:HK stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Medical Distribution sector in the HK exchange.
Based on this 2607:HK may be fairly valued for its sector
The last closing price of 2607:HK's stock was HKD 10.78.
The most recent market capitalization for 2607:HK is HKD 54.73B.
Unfortunately we do not have enough analyst data on 2607:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Shanghai Pharmaceuticals Holding Co Ltd's stock.
As per our most recent records Shanghai Pharmaceuticals Holding Co Ltd has 47,877 Employees.
Shanghai Pharmaceuticals Holding Co Ltd's registered address is Shanghai Pharmaceutical Building, Shanghai, China, 200020.
You can get more information about it from Shanghai Pharmaceuticals Holding Co Ltd's website at https://www.sphchina.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 2607:HK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
